Latest News and Press Releases

Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader...

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to...

LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has been granted Innovation Passport designation for OTL-201, an investigational haemopoietic...

New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing...

New York, USA, April 29, 2026 (GLOBE NEWSWIRE) -- Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsight The metagenomics sequencing market is...

New York, USA, April 29, 2026 (GLOBE NEWSWIRE) -- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight The IgAN market is growing due to...

The hearing loss gene therapy market size was valued at USD 1.12 bn in 2025 and is predicted to hit around USD 6.32 bn by 2035, rising at 18.90% CAGR.

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an...

- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine -  - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application...